Swiss pharmaceutical company Acino launches first cholesterol-lowering drug produced in UAE
Acino, a provider of pharmaceutical products and services in the region, recently held a cardiovascular disease summit at the Swiss pavilion, Expo, to raise awareness about cardiovascular disease (CVD). “Our goal is to have a positive impact wherever we operate,” said Andrew Bird, Managing Director and Head of Middle East, Turkey and Africa at Acino. “By bringing together the UAE’s leading experts on cardiovascular diseases, we hope to raise awareness and find new approaches for their prevention and treatment.
The CVD Summit is one of the company’s recent efforts to expand its regional presence which began last July when Acino partnered with UAE-based Pharmax for licensing, manufacture and supply of certain Acino products. The summit included the launch of Acino’s first locally manufactured drug produced under this partnership agreement. The cholesterol-lowering drug is used for the prevention and treatment of cardiovascular diseases.
“Cardiovascular disease is the leading cause of death everywhere, claiming more than 18 million lives each year and unfortunately the Middle East is no exception,” said Jean-Luc Eiselé, CEO of the World Heart Federation. “We advocate for equitable access to prevention, treatment and care. Our collaboration with key partners, such as Acino, is crucial if we are to achieve cardiovascular health for all.